*SCALPSWINGSTRADDLE*

[Zephyr]

yes...small company...24 employees.

http://finance.yahoo.com/q/pr?s=TTHI+Profile

Transition Therapeutics Inc., a biopharmaceutical company, researches and develops therapeutic agents for disease indications in Canada. The company's lead central nervous system drug candidate is ELND005, a Phase II clinical trial product used for the treatment of agitation/aggression associated with Alzheimer's disease and Down syndrome; and lead metabolic drug candidate is TT401, a Phase II clinical study for the treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics Inc. has a licensing and collaboration agreement with Eli Lilly to develop and commercialize rights to type 2 diabetes drug candidate TT401. The company was formerly known as Transition Therapeutics and Diagnostics Inc. and changed its name to Transition Therapeutics Inc. in December 2000. Transition Therapeutics Inc. was founded in 1987 and is headquartered in Toronto, Canada.